Kampmann Melissa S. Sells 2,645 Shares of Zoetis Inc. (NYSE:ZTS)

Kampmann Melissa S. trimmed its position in Zoetis Inc. (NYSE:ZTS) by 13.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,420 shares of the company’s stock after selling 2,645 shares during the period. Zoetis makes up approximately 2.2% of Kampmann Melissa S.’s investment portfolio, making the stock its 22nd largest holding. Kampmann Melissa S.’s holdings in Zoetis were worth $2,838,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new stake in shares of Zoetis in the third quarter valued at about $31,000. Dunhill Financial LLC raised its holdings in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares in the last quarter. Atlantic Edge Private Wealth Management LLC raised its holdings in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its holdings in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Finally, Quarry LP raised its holdings in Zoetis by 45.9% during the third quarter. Quarry LP now owns 305 shares of the company’s stock worth $60,000 after acquiring an additional 96 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley dropped their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays upped their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Piper Sandler boosted their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average target price of $215.90.

Insiders Place Their Bets

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,862 shares of company stock worth $312,254 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $163.76 on Thursday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The stock’s 50 day moving average is $166.81 and its 200-day moving average is $175.75. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $73.33 billion, a price-to-earnings ratio of 29.94, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.